Human Creation Holdings, Inc.
Notice Regarding Revision of Full-Year Earnings Forecast, Next Fiscal Year Forecast, and Recording of Extraordinary Loss on October 15, 2026
Revised consolidated full-year earnings forecast for the fiscal year ending September 2026. Net sales: 9,432 million yen; Operating income: 420 million yen; Ordinary income: 408 million yen; Net income attributable to owners of parent: -184 million yen; Net income attributable to owners of parent per share: -59.52 yen. An extraordinary loss of 400 million yen is expected to be recorded. Consolidated full-year forecast for the next fiscal year ending September 2027: Net sales 11,000 million yen; Operating income 470 million yen; Ordinary income 450 million yen; Net income attributable to owners of parent 265 million yen; Net income per share 85.04 yen.
Key Figures
- Net Sales: 9,432 million yen (vs. previous forecast -572 million yen / -5.7%)
- Operating Income: 420 million yen (vs. previous forecast -365 million yen / -46.4%)
- Ordinary Income: 408 million yen (vs. previous forecast -370 million yen / -47.5%)
AI要約
Revision of Earnings and Recording of Extraordinary Loss
In today's announcement, due to prolonged contract closings for HCFA and some unsuccessful projects, consolidated net sales and profit forecasts for the fiscal year ending September 2026 are expected to be below the previous forecast. In addition, related to fraudulent transactions by an employee of a Cosmopear client, an extraordinary loss of 400 million yen is expected to be recorded in the same period. As a result, net income is also expected to decline significantly.
Outlook for Next Fiscal Year and Future Policy
The consolidated full-year forecast for the fiscal year ending September 2027 is net sales 11,000 million yen; operating income 470 million yen; ordinary income 450 million yen; net income attributable to owners of parent 265 million yen; net income per share 85.04 yen. The company expects year-on-year revenue and profit growth through reduced reliance on HCFA, contributions from Life Shield, and profitability improvements in the SES business. The impacts of potential new M&A are not factored in and the company will disclose revisions as necessary.
Human Creation Holdings, Inc.
Company overview · Stock price · Financial data · All IR
